RE and Probiotics in MAFLD/NAFLD

Study population: Patients diagnosed with non-alcoholic or metabolically mediated fatty liver disease (NAFLD/MAFLD), including the inflammatory form (NASH), confirmed by imaging (ultrasound, MRI-PDFF) or histopathological (liver biopsy) methods. Inclusion criteria: * Diagnosis of NAFLD/MAFLD or NASH (imaging or histological confirmation of fatty liver disease, e.g., ultrasound, MRI-PDFF, biopsy) * Age 18-60 years * Ability to understand the study procedures and provide informed consent. * Stable clinical condition for at least 3 months prior to study initiation. Exclusion criteria: * Lack of fluency in English or Polish * Significant (structural) limitation of upper and/or lower limb mobility * Pregnancy or breastfeeding * Inability to understand instructions * Shift work * Participation in any study or research project within the last 3 months * Participation in an interventional drug study within the last 3 months * Participants with hepatic steatosis and regular alcohol consumption \> 30 g/day * Individuals with any concomitant liver disease (viral hepatitis, drug-induced liver injury, metabolic/genetic diseases (e.g., Wilson's disease)) * Anticoagulant/antiplatelet therapy, antithrombotic therapy, immunosuppressive medications, prolonged immunosuppression (e.g., recent cytotoxic chemotherapy, HIV infection with CD4 count \< 240), antibiotics, corticosteroids, valproic acid, amiodarone, tamoxifen within 3 months prior to study enrollment * Use of medications such as st…